Proactively manage your pharmacy inventory
Drug patents …
… from Kazakhstan to Kalamazoo
Manage your formulary budget
Deep knowledge on
small-molecule drugs and
the 110,000 global patents
Anticipate generic drug launch
Find generic entry opportunities
Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing
|Title:||Oleaginous pharmaceutical and cosmetic foam|
|Abstract:||The invention relates to stable oleaginous cosmetic or therapeutic foam compositions containing certain active agents, having unique therapeutic properties and methods of treatment using such compositions. The foamable composition includes at least one solvent selected from a hydrophobic solvent, a silicone oil, an emollient, a co-solvent, and mixtures thereof, wherein the solvent is present at a concentration of about 70% to about 96.5% by weight of the total composition, at least a non-ionic surface-active agent at a concentration of about 0.1% to less than about 10% by weight of the total composition; at least one gelling agent at a concentration of about 0.1% to about 5% by weight of the total composition; a therapeutically effective amount of at least one active agent; and at least one liquefied or compressed gas propellant, at a concentration of about 3% to about 25% by weight of the total composition.|
|Inventor(s):||Tamarkin; Dov (Ness Ziona, IL), Friedman; Doron (Karmei Yosef, IL), Eini; Meir (Ness Ziona, IL), Besonov; Alex (Rehovot, IL)|
|Assignee:||Foamix Ltd. (Rehovot, IL)|
|Filing Date:||Sep 14, 2010|
|Claims:||1. An oleaginous foamable therapeutic composition, comprising: a. about 70% to about 96.5% of a solvent phase, wherein the solvent phase is selected from the group consisting of a hydrophobic solvent, a silicone oil, and mixtures thereof; b. at least one non-ionic surface-active agent at a concentration of about 0.1% to about 10% by weight of the total composition; c. at least one gelling agent at a concentration of about 0.1% to about 5% by weight of the total composition; d. at least one active agent; e. at least one potent solvent selected from the group consisting of a hydrophobic solvent other than mineral oil; a co-solvent; an emollient; and mixtures thereof, wherein the potent solvent solubilizes the active agent substantially better than mineral oil solubilizes the active agent; and f. at least one liquefied or compressed gas propellant, wherein the composition forms a thermally stable breakable foam upon release from a pressurized container that collapses upon application of shear force; and wherein the water content of the composition is less than about 30% by weight. |
2. The oleaginous composition of claim 1, wherein the potent solvent solubilizes the active agent at least 5-fold better than mineral oil solubilizes the active agent.
3. The oleaginous composition of claim 1, wherein the potent solvent solubilizes the active agent at least 10-fold better than mineral oil solubilizes the active agent.
4. The oleaginous composition of claim 1, wherein the potent solvent is one or more potent solvents selected from the group consisting of polyethylene glycol, a polyol, benzyl alcohol, DMSO, ethyl oleate, ethyl caprylate, diisopropyl adipate, dimethylacetamide, N-methylpyrrolidone, N-hydroxyethylpyrrolidone, polyvinylpyrrolidone, isosorbide derivatives, dimethyl isosorbide, glycofurol, ethoxydiglycol, and mixtures thereof.
5. The oleaginous foamable therapeutic composition of claim 4, wherein said polyol is selected from the group consisting of glycerol, ethylene glycol, propylene glycol, hexylene glycol, diethylene glycol, a propylene glycol n-alkanol, a terpene, a di-terpene, a tri-terpene, a terpen-ol, limonene and I-menthol dioxolane.
6. The oleaginous foamable therapeutic composition of claim 4, wherein said polyethylene glycol is a liquid selected from the group consisting of PEG200, PEG300, PEG400 and PEG600.
7. The oleaginous composition of claim 1, further comprising at least one foam adjuvant selected from the group consisting of fatty alcohols having greater than or equal to 15 carbons, fatty acids having greater than or equal to 16 carbons, and mixtures thereof.
8. The oleaginous composition of claim 1, wherein the hydrophobic solvent is one or more hydrophobic solvents selected from the group consisting of mineral oil, triglyceride oil, silicone oil, an ester of a dicarboxylic acid, an ester of a fatty acid, a polyunsaturated oil, an unsaturated oil, an essential oil, and mixtures thereof.
9. The oleaginous composition of claim 1, wherein the solvent phase comprises at least one hydrophobic solvent and the potent solvent is at least one co-solvent.
10. The oleaginous composition of claim 9, wherein the mixture of the hydrophobic solvent and the one co-solvent comprises a weight ratio of about 1:8 to about 8:1.
11. The oleaginous composition of claim 1, wherein the composition is an emulsion.
12. The oleaginous composition of claim 1, further comprising at least one ionic surface-active agent, wherein the mixture of the non-ionic surface-active agent and the ionic surface-active agent is present at a weight ratio of about 20:1 to about 1:1 non-ionic surfactant surface-active agent to ionic surfactant surface-active agent.
13. The oleaginous composition of claim 1, wherein the concentration of the nonionic surfactant surface-active agent is from about 0.1% to about 2%.
14. The oleaginous composition of claim 1, wherein the gelling agent is one or more gelling agents selected from the group consisting of natural polymeric materials, semi-synthetic polymeric materials, synthetic polymeric materials, inorganic gelling agents and mixtures thereof.
15. The oleaginous composition of claim 1, wherein the water content is less than about 20% by weight.
16. The oleaginous composition of claim 1 wherein the specific gravity of the foam is about 0.01 g/mL to about 0.3 g/mL.
17. The oleaginous composition of claim 1, wherein the active agent is selected to treat a dermatological or mucosal disorder that is bacterial, fungal, viral, parasitic, inflammatory, autoimmune, allergic, hormonal, malignant and combinations thereof.
18. The oleaginous composition of claim 1, wherein at least one active agent is hydrophobic, having solubility in distilled water at ambient temperature of less than about 1 gm per 100 mL.
19. The oleaginous composition of claim 1, wherein at least one active agent is hydrophobic, having solubility in distilled water at ambient temperature of less than about 0.1 gm per 100 mL.
20. The oleaginous composition of claim 1, wherein at least one active agent is one or more therapeutic agents selected from the group consisting of an anti-infective, an antibiotic agent, an antibacterial agent, a macrolide, erythromycin, clindamycin, a sulfonamide, sulfanilamide, sulfadiazine, sulfacetamide, mupirocin, a tetracycline, tetracycline, doxycycline, a semi-synthetic penicillin, a beta-lactam, cloramphenicol, a dicarboxylic acid, azelaic acid, a salicylate, a peptide antibiotic, a cyclic peptide, cyclosporine, an oxidant, a free radical liberating compound, a bleaching agent, an iodine compound, benzoyl peroxide, an antifungal agent, an imidazole, a triazole, miconazole, fluconazole, ketoconazole, clotrimazole, itraconazole griseofulvin, ciclopirox, amorolfine, terbinafine, amphotericin B, potassium iodide, flucytosine, an antiviral agent, an antiparasitic agent, an anti-inflammatory agent, anonsteroidal anti-inflammatory agent, an oxicam, piroxicam, isoxicam, tenoxicam, sudoxicam, a salicylate, salicylic acid, ethyl salicylate, methyl salycilate, aspirin, disalcid, benorylate, trilisate, safapryn, solprin, diflunisal, fendosal, an acetic acid derivative, diclofenac, fenclofenac, indomethacin, sulindac, tolmetin, isoxepac, furofenac, tiopinac, zidometacin, acematacin, fentiazac, zomepirac, clindanac, oxepinac, felbinac, and ketorolac, a fenamate, mefenamic, meclofenamic, flufenamic, niflumic, tolfenamic acid, a propionic acid derivative, ibuprofen, naproxen, benoxaprofen, flurbiprofen, ketoprofen, fenoprofen, fenbufen, indopropfen, pirprofen, carprofen, oxaprozin, pranoprofen, miroprofen, tioxaprofen, suprofen, alminoprofen, tiaprofenic,a pyrazoles, phenylbutazone, oxyphenbutazone, feprazone, azapropazone, trimethazone, an antihistamine, doxepin, phrilamine maleate, chlorpheniramine, tripelennamine, phenothiazines, promethazine hydrochloride, dimethindene maleate, an anesthetic agent, benzocaine, lidocaine, bupivacaine, chlorprocaine, dibucaine, etidocaine, mepivacaine, tetracaine, dyclonine, hexylcaine, procaine, cocaine, ketamine, pramoxine, an analgesic agent, an antiallergic agent, a corticosteroid, clobetasol proprionate, halobetasol proprionate, betamethasone, betamethasone diproprionate, betamethasone valerate, fluocinolone, halcinonide, etamethasone valerate, fluocinolone acetonide, hydrocortisone, Triamcinolone, a lubricating agent, an antiproliferative, a cortisone, an immunosuppressant, an immunoregulating agent, an immunomodulator, tacrolimus, tresperimus, pimecrolimus, sirolimus, verolimus, laflunimus, laquinimod, Imiquimod, a keratolytic agent, a alpha-hydroxy acid, lactic acid, glycolic acid, a betahydroxy acids, urea, a retinoid, retinol, retinal, retinoic acid, etretinate, actiretin, isotretinoin, adapalene, tazarotene, an anti-acne agent, azelaic acid, an azelaic acid derivative an anti cancer agent, an antiproliferative drugs, 5-fluorouracil, a photodynamic therapy agent, a vitamin or a vitamin derivative, an anti-wrinkle agent, a radical scavenger, a self-tanning agent, a skin whitening agent, a skin protective agent, an anti-cellulite agent, a massaging oil, an anti-wart agent, a lubricating agent.sub.. and mixtures thereof.
21. The oleaginous composition of claim 20, wherein the therapeutic agent is selected for the treatment of a disorder of the skin, mucosal membrane, ear channel, vagina, penile urethra, colon, and rectum.
22. A method of treating, alleviating or preventing a dermatological, mucosal or cosmetic disorder or disease, comprising administering topically to a subject having said disorder a therapeutically effective amount of an oleaginous foam composition according to claim 1.
23. The method of claim 22, wherein the composition is applied topically to a target selected from the group consisting of the skin, mucosal membrane, ear channel, vagina, penile urethra, colon and rectum.
24. The method of claim 22, wherein the disorder or disease is selected from the group consisting of a. a dermatitis, contact dermatitis, atopic dermatitis, seborrheic dermatitis, nummular dermatitis, chronic dermatitis, generalized exfoliative dermatitis, stasis dermatitis; lichen simplex chronicus; diaper rash; a bacterial infection, cellulitis, acute lymphangitis, lymphadenitis, erysipelas, cutaneous abscess, necrotizing subcutaneous infections, staphylococcal scalded skin syndrome, folliculitis, furuncles, hidradenitis suppurativa, carbuncles, paronychial infection, erythrasma, a fungal infection, a dennatophyte infection, a yeast infection, a parasitic infection, scabies, pediculosis, creeping eruption, a viral infection, a disorder of hair follicles, a disorder of sebaceous glands, acne, rosacea, perioral dermatitis, hypertrichosis, hirsutism, alopecia, male pattern baldness, alopecia areata, alopecia universalis, alopecia totalis, pseudofolliculitis barbae, keratinous cyst, a scaling papular disease, psoriasis, pityriasis rosea, lichen planus, pityriasis rubra pilaris, a benign tumor, moles, dysplastic nevi, skin tags, lipomas, angiomas, pyogenic granuloma, seborrheic keratoses, dennatofibroma, keratoacanthoma, keloid, a malignant tumor, basal cell carcinoma, squamous cell carcinoma, melanoma, paget's disease of the nipples, kaposi's sarcoma, reactions to sunlight, sunburn, chronic effects of sunlight, photosensitivity, a bullous disease, pemphigus, bullous pemphigoid, dermatitis herpetiformis, linear immunoglobulin A disease, a pigmentation disorder, hypopigmentation, vitiligo, albinism, postinflammatory hypopigmentation, hyperpigmentation melasma, chloasma, drug-induced hyperpigmentation, postinflammatory hyperpigmentation, a disorder of cornification, ichthyosis, keratosis pilaris, calluses, corns, actinic keratosis, pressure sores, a disorder of sweating, an inflammatory reaction, drug eruption, toxic epidermal necrolysis, erythema multifonne, erythema nodosum, granuloma annulare; b. a non dermatological disorder which responds to topical or transdermal delivery of an active agent, localized pain in general, joint pain, muscle pain, back pain, rheumatic pain, arthritis, ostheoarthritis, acute soft tissue injury, sports injuries; c. a condition which responds to hormone therapy, a disorder which responds to hormone replacement therapy, a disorder which responds to transdermal nicotine administration; d. a disorder of a body cavity, the rectum, vagina, penile urethra, or ear canal; e. pelvic pain, premenstrual syndrome, mittelschmerz, midcycle pain, midcycle pain due to ovulation, dysmenorrhea, endometriosis, ectopic pregnancy, ovarian cysts and masses, acute pelvic inflammatory disease, pelvic congestion syndrome, vulvodynia, a vulvovaginal infection, bacterial vaginosis, candidal vaginitis, trichomonas vaginalis, herpes simplex, genital ulcer, genital warts, pelvic inflammatory disease, cervicitis, acute and chronic salpingitis; endometriosis; gynecological neoplasms, endometrial cancer, ovarian cancer, cervical cancer, vulvar cancer, vaginal cancer, fallopian tube cancer, gestational trophoblastic disease, a benign tumor, a sexually transmitted disease, a sexual dysfunction disorder, sexual arousal disorder, female orgasmic disorder, dyspareunia, vaginismus, a gynecological disorder that respond to hormonal therapy; f. rectal abscess, rectal fistula, anal cancer, anal warts, Crohn's disease, haemorrhoids, anal pruritus, perianal pruritus, anal soreness, anal excoriation, perianal thrush, anal fissures, fecal incontinence, constipation, polyps of the colon and rectum; and g. an intra-vaginal or rectal sexually-transmitted and non-sexually-transmitted infectious disease.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.